Comparative Pharmacology
Head-to-head clinical analysis: ARYMO ER versus DARVON N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYMO ER versus DARVON N.
ARYMO ER vs DARVON-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYMO ER (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception. It also activates descending inhibitory pathways.
Propoxyphene is a weak mu-opioid receptor agonist that produces analgesia by binding to opioid receptors in the central nervous system, altering the perception of and response to pain. Its metabolite norpropoxyphene has local anesthetic and sodium channel blocking effects, which may contribute to cardiac toxicity.
15 mg to 30 mg orally every 12 hours; titrate to effect; maximum 60 mg per dose.
100 mg orally every 4 hours as needed for pain; maximum 600 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 11–13 hours in healthy adults. This extended half-life compared to immediate-release morphine (2–4 hours) allows for once-daily dosing. In elderly or hepatic/renal impairment, half-life may be prolonged up to 22 hours.
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours. Accumulation of norpropoxyphene on repeated dosing increases risk of toxicity.
Primarily renal (90%), with approximately 10% excreted unchanged in urine; the remainder as glucuronide conjugates (morphine-3-glucuronide, morphine-6-glucuronide) and minor metabolites. Biliary/fecal excretion accounts for <10%.
Primarily renal (approximately 70% as unchanged drug and glucuronide conjugates); minor biliary/fecal elimination (25-30%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic